| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Antitumor activity of HER1/EGFR tyrosine kinase inhibitor erlotinib, alone and in combination with CPT-11 (irinotecan) in human colorectal cancer xenograft models
|
Chen, Jianping
|
|
2006
|
59 |
5 |
p. 651-659
|
artikel
|
| 2 |
Antitumour action of 5,6-dimethylxanthenone-4-acetic acid in rats bearing chemically induced primary mammary tumours
|
Liu, Johnson J.
|
|
2006
|
59 |
5 |
p. 661-669
|
artikel
|
| 3 |
A phase I study of paclitaxel, cisplatin, and fluorouracil (TCF) for advanced gastric cancer
|
Hara, Takuo
|
|
2006
|
59 |
5 |
p. 631-636
|
artikel
|
| 4 |
Are capecitabine and oxaliplatin (XELOX) suitable treatments for progressing low-grade and high-grade neuroendocrine tumours?
|
Bajetta, Emilio
|
|
2006
|
59 |
5 |
p. 637-642
|
artikel
|
| 5 |
Chronomodulated administration of oxaliplatin plus capecitabine (XELOX) as first line chemotherapy in advanced colorectal cancer patients: phase II study
|
Santini, Daniele
|
|
2006
|
59 |
5 |
p. 613-620
|
artikel
|
| 6 |
Dihydrodiol dehydrogenase in drug resistance and sensitivity of human carcinomas
|
Pan, Bih Fang
|
|
2006
|
59 |
5 |
p. 697-702
|
artikel
|
| 7 |
Gemcitabine and vinorelbine in recurrent advanced non-small cell lung cancer: sequence does matter
|
Juergens, Rosalyn
|
|
2006
|
59 |
5 |
p. 621-629
|
artikel
|
| 8 |
Histological changes in bladders of patients submitted to ifosfamide chemotherapy even with mesna prophylaxis
|
Lima, Marcos Venício Alves
|
|
2006
|
59 |
5 |
p. 643-650
|
artikel
|
| 9 |
In vitro anti-cancer activity and structure–activity relationships of natural products isolated from fruits of Panax ginseng
|
Wang, Wei
|
|
2006
|
59 |
5 |
p. 589-601
|
artikel
|
| 10 |
Pharmacodynamic and toxicokinetic evaluation of the novel MEK inhibitor, PD0325901, in the rat following oral and intravenous administration
|
Brown, Alan P.
|
|
2006
|
59 |
5 |
p. 671-679
|
artikel
|
| 11 |
Pharmacokinetics of 5,6-dimethylxanthenone-4-acetic acid (AS1404), a novel vascular disrupting agent, in phase I clinical trial
|
Jameson, M. B.
|
|
2006
|
59 |
5 |
p. 681-687
|
artikel
|
| 12 |
Pharmacokinetics of low-dose nedaplatin and validation of AUC prediction in patients with non-small-cell lung carcinoma
|
Niioka, Takenori
|
|
2006
|
59 |
5 |
p. 575-580
|
artikel
|
| 13 |
Phase I dose-escalation study of a novel antitumor agent, SR271425, administered intravenously in split doses (d1–d2–d3) in patients with refractory solid tumors
|
Campone, M.
|
|
2006
|
59 |
5 |
p. 689-695
|
artikel
|
| 14 |
Phase I study of weekly DN-101, a new formulation of calcitriol, in patients with cancer
|
Beer, Tomasz M.
|
|
2006
|
59 |
5 |
p. 581-587
|
artikel
|
| 15 |
Role of nitric oxide on pathogenesis of 5-fluorouracil induced experimental oral mucositis in hamster
|
Leitão, R. F. C.
|
|
2006
|
59 |
5 |
p. 603-612
|
artikel
|
| 16 |
Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models
|
Chang, Yong S.
|
|
2006
|
59 |
5 |
p. 561-574
|
artikel
|
Tijdschrift beschrijving